Cover Image
市場調查報告書

生物模擬技術的全球市場

Biosimulation Technology

出版商 Global Industry Analysts, Inc. 商品編碼 341978
出版日期 內容資訊 英文 164 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物模擬技術的全球市場 Biosimulation Technology
出版日期: 2015年09月01日 內容資訊: 英文 164 Pages
簡介

本報告涵括生物模擬技術的全球市場,提供您美國,加拿大,日本,歐洲,亞太地區,南美,及其他地區等各地區之個別分析,2013年∼2020年各年的實際成果/估計及預測,再彙整42家主要企業及利基企業之公司簡介。

第1章 簡介,調查方法,產品定義

  • 調查的可靠性和報告的限制
  • 免責聲明
  • 資料的解釋和報告水準
    • 定量技術及分析法
  • 產品的定義和調查範圍

第2章 摘要整理

  • 產業概要
    • 生物模擬:是藥物研究開發上一大優點
    • 現在及未來分析
    • 應用領域和終端用戶領域
    • 生物模擬提供藥物開發的模式轉移
    • 主要市場發展推動因素概要
    • 市場發展阻礙因素
    • 競爭
  • 市場發展推動因素
    • 醫療費的增加促進藥物研發及藥物開發需求
    • CDD的發生數量及盛行率的增加:主要的發展推動因素
    • 全世界人口的高齡化促使先進性藥物的研究開發
    • 傳統藥物研發相關高成本
    • 臨床試驗後期的高失敗率
    • 最近臨床試驗後期的失敗案例清單 (2014年)
    • 中國與印度:研究開發投資的熱點
    • 生物模擬克服了小兒科開發藥劑中課題
  • 市場趨勢‐考察
    • 模擬工具可去除擴大中的生命科學研究開發預算的壓力
    • 生物模擬突破了神經退化性疾病的瓶頸
    • 顯示出糖尿病研究的新道路
    • 生物模擬從開發支援轉移到臨床工具
    • 肺生物模擬:為OIP開發帶來變革
    • 藥物重新配置的生物模擬
    • 電網型對接支援生物模擬
    • 更優秀模式的需求:促使市場上創新的主要原因
  • 技術概要
    • 生物模擬:簡單的介紹
    • 藥物研發和藥物開發
    • 藥物開發過程的各階段
    • 藥物開發技術
    • 人生理學
    • 數學的模式和生物模擬技術
    • Bottom-Up(由下而上)建模
    • Top-Down(由上而下)建模
  • 產品的發表/認證
  • 最新產業趨勢
  • 主要的國際企業
  • 全球市場的展望

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
  • 南美
  • 其他地區

第4章 競爭情形

目錄
Product Code: MCP-7920

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.
Biovia
Certara L.P
Chemical Computing Group
Entelos, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biosimulation: Massively Benefiting Drug R&D
  • Current and Future Analysis
  • Application and End-user Areas
    • Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)
    • Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)
  • Biosimulation Offers Paradigm Shift in Drug Development
  • Key Market Drivers in a Nutshell
  • Market Restraints
  • Competition

2. GROWTH DRIVERS

  • Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development
    • Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
    • Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
    • Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)
    • Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Aging Global Population Drives Advanced Drug R&D
    • Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • High Costs Associated with Traditional Drug Discovery
    • Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
    • Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)
  • High Failure Rate of Late-Stage Drug Trials
  • List of Recent Late-stage Drug Failures (2014)
  • China and India: Hot Spots for R&D Investment
    • Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)
  • Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS - AN INSIGHT

  • Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets
    • Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)
  • Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
  • Marking New Avenues in Diabetes Research
  • Biosimulation Moving From Discovery Aid to Clinical Tool
  • Lung Biosimulation: Game Changer for OIP Development
  • Biosimulation for Drug Repositioning
  • Grid-based Docking Aids Biosimulation
  • Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

  • Biosimulation - A Brief Introduction
  • Drug Discovery and Development
  • Stages in Drug Development Process
    • Target identification
    • Target Validation
    • Lead Identification
    • Lead Optimization
    • Pre-Clinical Testing
    • Clinical Trials
  • Drug Discovery Technologies
  • Human Physiology
  • Mathematical Models and Biosimulation Technique
  • Bottom-up Modeling
  • Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

  • Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0
  • Optimata Granted US Patent for Biosimulation Technology
  • Cognigen Releases Version 1.3 of KIWI™
  • Simulations Plus Releases Version 9.0 of GastroPlus™
  • Certara Launches Version 2.0 of Cardiac Safety Simulator
  • Certara Releases Version 14 of Simcyp™ Simulator
  • Certara Receives FDA Grant for MechDermA
  • Physiomics Launches EasyAP™
  • Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
  • Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

  • Certara Merges Its Pharsight Consulting with Quantitative Solutions
  • Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
  • Physiomics Signs Contract with Merck Serono
  • PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions
  • CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
  • Dassault Systemes Acquires Accelrys
  • Rhenovia Pharma Secures Series B Funding
  • Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
  • Arsenal Capital Partners Acquires Certara
  • Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Advanced Chemistry Development, Inc. (Canada)
  • Biovia (Formerly Accelrys) (US)
  • Certara L.P. (US)
  • Chemical Computing Group (Canada)
  • Entelos, Inc. (US)
  • In Silico Biosciences, Inc. (US)
  • InhibOx (UK)
  • Insilico Biotechnology AG (Germany)
  • LeadInvent Technologies (India)
  • Leadscope, Inc. (US)
  • Nimbus Therapeutics (US)
  • OpenEye Scientific Software Inc. (US)
  • Physiomics Plc. (UK)
  • Rhenovia Pharma SAS (France)
  • Schrodinger, LLC (US)
  • Simulations Plus, Inc.(US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Biosimulation to Abate Life Sciences R&D Spending
    • Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)
    • Ageing Population - Booster for Effective Drug Development
    • Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Rise in Chronic Disorders Drive Market Growth
    • Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)
    • Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)
    • Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Increasing Incidence of Cancer: A Major Growth Driver
    • Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Demand for Advanced Drug Development
    • Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Regulatory Authorities Stress on Paradigm Shift in Drug Development
    • Ageing Population Boosts Demand
    • Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Rhenovia Pharma SAS - A Key Player
  • B. Market Analytics
    • Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Insilico Biotechnology AG - A Key Player
  • B. Market Analytics
    • Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Growing Population and Aging Demographic Drive Demand for Advanced Drug Development
    • Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
    • Leadinvent Technologies (India) - A Key Player
  • B. Market Analytics
    • Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top